p.146 抽出テキスト
IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents. Cardiovasc Intervent Radiol 2020; 43: 215-222. PMID: 31690980 462. Golzar J, Soga Y, Babaev A, et al. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent. J Endovasc Ther 2020; 27: 296-303. PMID: 31989856 463. Soga Y, Ando K. “Low Echoic Area” around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease. SAGE Open Med Case Rep 2021 May 12. doi: 10.1177/2050313X211014519 PMID: 34026211 464. Soga Y, Fujihara M, Tomoi Y, et al. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease. J Atheroscler Thromb 2020; 27: 164-171. PMID: 31257301 465. Tepe G, Laird J, Schneider P, et al. IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015; 131: 495-502. PMID: 25472980 466. Soga Y, Iida O, Urasawa K, et al. Three-Year Results of the IN- .PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty. J Endovasc Ther 2020; 27: 946-955. PMID: 32865145 467. Horie K, Tanaka A, Suzuki K, et al. Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions. CVIR Endovasc 2021; 4: 13. PMID: 33428019 468. Rosenfield K, Jaff MR, White CJ, et al. LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med 2015; 373: 145-153. PMID: 26106946 469. deleted in proof. 470. Sachar R, Soga Y, Ansari MM, et al. RANGER II SFA Investigators. 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon. JACC Cardiovasc Interv 2021; 14: 1123-1133. PMID: 34016410 471. Steiner S, Schmidt A, Zeller T, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J 2020; 41: 2541-2552. PMID: 31989155 472. Iida O, Takahara M, Soga Y, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. JACC Cardiovasc Interv 2014; 7: 792-798. PMID: 25060024 473. Soga Y, Takahara M, Iida O, et al. Relationship Between Primary Patency and Lesion Length Following Bare Nitinol Stent Placement for Femoropopliteal Disease. J Endovasc Ther 2015; 22: 862-867. PMID: 26438352 474. Soga Y, Iida O, Hirano K, et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg 2011; 54: 1058-1066. PMID: 21880459 475. Soga Y, Hamasaki T, Edahiro R, et al. STOP-IC investigators. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study. J Endovasc Ther 2018; 25: 306-312. PMID: 29706129 476. Soga Y, Shintani Y, Hamasaki T, et al. ESPALIER Investigators. Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study. Cardiovasc Interv Ther 2017; 32: 325-332. PMID: 27456034 477. Garcia L, Jaff MR, Metzger C, et al. SUPERB Trial Investigators. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SU- PERB Trial. Circ Cardiovasc Interv 2015; 8: e000937. PMID: 25969545 478. Iida O, Takahara M, Soga Y, et al. A Novel Angiographic Risk Score for Femoropopliteal Interventions. J Endovasc Ther 2020; 27: 967- 973. PMID: 32813589 479. Soga Y, Iida O, Suzuki K, et al. Initial and 3-year results after subintimal versus intraluminal approach for long femoropopliteal occlusion treated with a self-expandable nitinol stent. J Vasc Surg 2013; 58: 1547-1555. PMID: 23910456 480. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2018; 7: e011245. PMID: 30561254 481. Nordanstig J, James S, Andersson M, et al. Mortality with Pacli- taxel-Coated Devices in Peripheral Artery Disease. N Engl J Med 2020; 383: 2538-2546. PMID: 33296560 482. Nakamura M, Takata M, Yokoi H, et al. An Individual-Level Meta-Analysis Using Real-World and Pivotal Studies on Mortality From the Use of Paclitaxel-Containing Devices in Japanese Femoropopliteal Disease Patients. Circ J 2021; 85: 2137-2145. PMID: 33952835 483. Shibutani S, Obara H, Matsubara K, et al. JMidterm Results of a Japanese Prospective Multicenter Registry of Heparin-Bonded Expanded Polytetrafluoroethylene Grafts for Above-the-Knee Femoropopliteal Bypass. Circ J 2020; 84: 501-508. PMID: 32062636 484. deFreitas DJ, Love TP, Kasirajan K, et al. Computed tomography angiography-based evaluation of great saphenous vein conduit for lower extremity bypass. J Vasc Surg 2013; 57: 50-55. PMID: 22963811 485. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: Observations from a large multicenter trial. J Vasc Surg 2007; 46: 1180-1190. PMID: 18154993 486. Neufang A, Espinola-Klein C, Savvidis S, et al. External polytetrafluoroethylene reinforcement of varicose autologous vein grafts in peripheral bypass surgery produces durable bypass function. J Vasc Surg 2018; 67: 1778-1787. PMID: 29242066 487. McQuade K, Gable D, Hohman S, et al. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg 2009; 49: 109-116. PMID: 19028055 488. Reijnen MMPJ, van Walraven LA, Fritschy WM, et al. 1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc Interv 2017; 10: 2320-2331. PMID: 29169500 489. Bosiers M, Setacci C, De Donato G, et al. ZILVERPASS study: ZILVER PTX stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther 2020; 27: 287-295. PMID: 31997715 490. Conte MS, Belkin M, Donaldson MC, et al. Femorotibial bypass for claudication: do results justify an aggressive approach? J Vasc Surg 1995; 21: 873-881. PMID: 7776466 491. Mii S, Tanaka K, Kyuragi R, et al. Raison d’etre of Tibial Artery Bypass for Intermittent Claudication in the Era of Endovascular Therapy. Circ J 2016; 80: 1460-1469. PMID: 27194373 492. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv 2011; 78: 611-617. PMID: 21805562 493. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315. PMID: 15653033 494. Lundell A, Lindblad B, Bergqvist D, et al. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: A prospective randomized study. J Vasc Surg 1995; 21: 26-34. PMID: 7823359 495. Mills JL Sr, Wixon CL, James DC, et al. The natural history of intermediate and critical vein graft stenosis: Recommendations for continued surveillance or repair. J Vasc Surg 2001; 33: 273-280. PMID: 11174778 496. Mofidi R, Flett M, Nagy J, et al. Balloon angioplasty as the primary treatment for failing infra-inguinal vein grafts. Eur J Vasc Endovasc Surg 2009; 37: 198-205. PMID: 19046905 497. Berceli SA, Hevelone ND, Lipsitz SR, et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: Analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg 2007; 46: 1173-1179. PMID: 17950564 498. Korzon-Burakowska A, Dziemidok P. Diabetic foot - the need for comprehensive multidisciplinary approach. Ann Agric Environ Med 2011; 18: 314-317. PMID: 22216805 499. Smith L, Fox M, Seriki D. The role of the community clinician in early detection, referral and treatment of critical limb ischaemia. Br J Community Nurs 2014; 19: 266-272. PMID: 24902054 500. 東信良,重松邦広,尾原秀明,ほか.包括的高度慢性下肢虚血の診療に関するGlobal Vascular Guidelines ポケットガイド日本語訳版.日血外会誌 2021;30:141-162. 501. Mätzke S, Lepäntalo M. Claudication does not always precede critical leg ischemia. Vasc Med 2001; 6: 77-80. PMID: 11530968 502. Shirasu T, Hoshina K, Yamamoto S, et al. Poor prognosis in critical limb ischemia without pre-onset intermittent claudication. Circ J 2015; 79: 1618-1623. PMID: 25925843 503. Khiabani HZ, Anvar MD, Rostad B, et al. The distribution of oede- ma in the lower limb of patients with chronic critical limb ischaemia: A study with computed tomography. Vasa 1999; 28: 265-270. PMID: 10611844